Premature menopause: management challenges after the Women's Health Initiative

Ayres, Julie

doi:10.1258/136218005775544363

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Women with POF are an often-overlooked and undertreated group and this represents a number of clinical management challenges [4][5][6][7] . There are currently no cures.…”

Section: Introductionmentioning

confidence: 99%

The silent grief: psychosocial aspects of premature ovarian failure

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Women with POF are an often-overlooked and undertreated group and this represents a number of clinical management challenges [4][5][6][7] . There are currently no cures.…”

Section: Introductionmentioning

confidence: 99%

The silent grief: psychosocial aspects of premature ovarian failure

et al. 2011

View full text Add to dashboard Cite

show abstract

“…In 1% POF women, POF occurs due to autoimmune ovarian damage or genetic aberrations involving the X chromosome, autosomes, or some specific genes [ 26 ]. What’s worse, women with POF are often neglected and under-treated, which represents many clinical management challenges [ 27 , 28 ]. Currently, the effective methods for the treatment of POF haven’t shown up.…”

Section: Discussionmentioning

confidence: 99%

Chrysin reduces inflammation and oxidative stress and improves ovarian function in D-gal-induced premature ovarian failure

Deng

2022

Bioengineered

View full text Add to dashboard Cite

Premature ovarian failure (POF), a frequently occurring pathology. Chrysin has antioxidant, anti-inflammatory, anti-apoptotic and other pharmacological activities. This study was designed to detect the effect of Chrysin on POF. The establishment of POF was depended on the subcutaneous injection of D-gal (200 mg/kg/d). With the adoption of ELISA, the levels of hormones and release of inflammatory cytokines were assayed. The expression of MDA, GSH-px, SOD and ROS was evaluated with corresponding kits. In addition, the pathological changes of ovary and apoptosis of ovarian granulosa cells in D-gal-induced mice were detected using H&E staining and TUNEL, respectively. Moreover, the levels of FSH receptor and apoptosis-related proteins were measured with western blot. Finally, ERβ expression was measured with RT-qPCR and western blot. In this study, we found that chrysin regulated the expression of hormones and weight of D-gal-induced mice. It was also found that chrysin inhibited the inflammation and oxidative stress in mice with D-gal induction. In addition, the number and advancement of follicle in D-gal-induced mice treated with chrysin revealed that chrysin could improve the ovarian function of mice with POF. Furthermore, chrysin exhibited inhibitory effects on the apoptosis of ovarian granulosa cells in D-gal-induced mice. More importantly, chrysin molecule targeted ERβ and activated ERβ expression in POF. Overall, Chrysin reduces inflammation and oxidative stress and improves ovarian function in D-gal-induced premature ovarian failure, suggesting that chrysin is valuable for the treatment of POF.

show abstract

“…However, concerns have been raised by some authors surrounding the reporting of the WHI and MWS trial results, and the fact that little coverage was given to the evidence of the reduced incidence of osteoporotic fractures and colon cancer (32). Both trials recruited women aged over 50 years; therefore, the results cannot be applied to women who undergo premature menopause (33). HRT for women with premature menopause (primary ovarian insufficiency), prescribed up to the age of natural menopause (~51 years), is endorsed by the British Menopause Society and NICE guidelines.…”

Section: Discussionmentioning

confidence: 99%

Age at menopause and hormone replacement therapy as risk factors for head and neck and oesophageal cancer

2017

View full text Add to dashboard Cite

There were ~986,000 cases of head and neck cancer (HNC) and oesophageal cancer diagnosed worldwide in 2012. The incidence of these types of cancer is much higher in males than females, although this disparity decreases in the elderly population, suggesting a role for hormones as a risk factor. This systematic review investigates the potential role of female hormones [age at menopause and use of hormone replacement therapy (HRT)] as risk factors for HNC/oesophageal squamous cell carcinoma (SCC). The electronic databases MEDLINE, Web of Science, EMBASE and Cochrane were searched. Only studies with at least 50 cases of HNC/oesophageal SCC, with data on age at menopause, smoking, alcohol, age and socioeconomic status or educational attainment, were included. The Newcastle Ottawa Scale was used for assessing risk of bias. Eight studies met the inclusion criteria (5 oesophageal SCC, 2 HNC and 1 combined oesophageal SCC and HNC). HRT was shown to reduce the risk of HNC (HR, 0.78; 95% CI, 0.61-0.99) in one study. Our results showed that earlier age at menopause is a risk factor for oesophageal SCC, with women entering menopause at <45 years having double the risk of those entering menopause at age >50 years. Similar, but less striking, results were observed for HNC. HRT was found to reduce the risk of HNC/oesophageal SCC, but the evidence is inconclusive. We, therefore, recommend that consideration should be given to collecting data on reproductive factors and exposure to HRT, as routine practice, in future epidemiological and clinical studies of these cancers. The concept of oestrogen deficiency as a risk for HNC/oesophageal SCC deserves further exploration in future laboratory and clinical studies.

show abstract

Premature menopause: management challenges after the Women's Health Initiative

Cited by 3 publications

References 0 publications

The silent grief: psychosocial aspects of premature ovarian failure

The silent grief: psychosocial aspects of premature ovarian failure

Chrysin reduces inflammation and oxidative stress and improves ovarian function in D-gal-induced premature ovarian failure

Age at menopause and hormone replacement therapy as risk factors for head and neck and oesophageal cancer

Contact Info

Product

Resources

About